For instance, inhibitors targeting NRF2-coactivator interactions or agonists restoring PPARα and FXR activity might counteract cholestasis or other metabolic dysfunctions in diseases including PFIC5 or NAFLD. Here, NFE2L2 is linked to cholestasis.